-+ 0.00%
-+ 0.00%
-+ 0.00%

Isofol Medical Q3 loss narrows 8% to SEK 12 million

PUBT·11/12/2026 07:24:43
Isofol Medical Q3 loss narrows 8% to SEK 12 million
  • Isofol Medical’s third-quarter 2026 loss narrowed 8% to SEK 12 million.
  • Cash and cash equivalents fell 29% to SEK 98.09 million at September 30, while third-quarter net revenue remained nil.
  • All patients in the ongoing arfolitixorin phase Ib/II study achieved disease control; half became candidates for tumor surgery.
  • No dose-limiting side effects have been observed, and preparations for phase II are underway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Isofol Medical AB published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.